• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Interferon‐based therapy reduces risk of stroke in chronic hepatitis C patients: a population‐based cohort study in Taiwan
ConclusionsInterferon‐based therapy may reduce the long‐term risk of stroke in patients with chronic HCV infection.
Source: Alimentary Pharmacology and Therapeutics - June 29, 2013 Category: Drugs & Pharmacology Authors: C.‐S. Hsu, J.‐H. Kao, Y.‐C. Chao, H. H. Lin, Y.‐C. Fan, C.‐J. Huang, P.‐S. Tsai Tags: Original Article Source Type: research

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research

Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
CONCLUSION: A 63-year-old man on a stable dose of warfarin experienced a decrease in INR values after the initiation of a 12-week course of sofosbuvir and ribavirin for the treatment of chronic HCV infection. PMID: 28596225 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - June 11, 2017 Category: Drugs & Pharmacology Authors: Peterson D, Van Ermen A Tags: Am J Health Syst Pharm Source Type: research

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
ConclusionExtrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti‐viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Source: Alimentary Pharmacology and Therapeutics - October 18, 2017 Category: Drugs & Pharmacology Authors: P. Cacoub, M. Vautier, A. C. Desbois, D. Saadoun, Z. Younossi Tags: ORIGINAL ARTICLE Source Type: research

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research